Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Holding MCRB?
Track your performance easily
MCRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.54 - $2.05
Previous Close$0.81
Volume4.17M
Average Volume (3M)3.88M
Market Cap
$117.54M
Enterprise Value$144.32M
Total Cash (Recent Filing)$66.82M
Total Debt (Recent Filing)$93.61M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 11, 2025EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding170,738,069
10 Day Avg. Volume4,071,279
30 Day Avg. Volume3,884,242
Standard Deviation0.83
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)5.81
Price to Sales (P/S)1836.50
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.26K
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$5.63Price Target Upside669.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Seres Therapeutics News
PremiumCompany Announcements
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
PremiumCompany Announcements
Seres Therapeutics Faces Nasdaq Challenge Amid Trial SuccessBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSER-155 demonstrated significant reduction of bloodstream infection in allo-HSCT patients.
Financial PerformanceThe sale of Vowst rights to Nestle resulted in significant net proceeds and future milestone payment opportunities.
Pipeline ExpansionSER-155 could expand into additional indications adjacent to allo-HSCT, maximizing the commercial value of SER-155.
Bears Say
Growth PotentialIt is difficult to find a near-term fundamental growth driver to help improve subdued sentiment on shares.
Pipeline UncertaintyThe pipeline at Seres is considered a 'show-me' story, suggesting skepticism about its potential without proven results.
Program AssessmentThere is a lack of definitive catalysts for the program, with future trial design and guidance needed to better assess the value of the program.
---
Ownership Overview
0.53% Insiders
12.07% Mutual Funds
14.46% Other Institutional Investors
69.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $0.54 and its highest was $2.05 in the past 12 months.
What is Seres Therapeutics’s market cap?
Currently, no data Available
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 109 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Nov 13, 2024. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.658.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is -$0.2.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 170,738,070 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of $0.58 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -10.606%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Among the largest hedge funds holding Seres Therapeutics’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics’s shares valued at 22M.
---
Seres Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.63 (669.34% Upside)
$5.63 (669.34% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.18%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-51.39%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
---
MCRB Earnings Call
Q3 2024
0:00 / 0:00
---
MCRB Stock 12 Month Forecast
Average Price Target
$5.63
▲(669.34% Upside)
Technical Analysis
Best Analysts Covering MCRB
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+118.42%
reiterated a sell rating 3 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +118.42% per trade.
---